SYN The new price target by Maxim is very nice and a long way off from here. On Schwab they have a nice write up of reasoning, I will try to find it elsewhere. Finviz has an article Short story -
8:58 am Synthetic Biologics target raised to $6 at Maxim Group following meetings with mgmt
Maxim Group raises its SYN tgt to $6 from $3. Firm concludes that there are now multiple events ahead, including top-line data for Trimesta (oral estriol) in relapsing/remitting multiple sclerosis in April. In addition, SYN-004 (a second-generation product) should progress to the clinic (for the start of a phase 1b/2 trial) for the prevention of C-difficile infection. SYN-005 (mAb) for pertussis (whooping cough) is another catalyst that has shown compelling animal data (whooping cough is an unmet medical need), as well as the development of SYN-010 for C-IBS and related GI disorders and SYN-001 for life-threatening Acinetobacter (gram negative bacterium) infections.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.